The New England journal of medicine
-
Editorial Comment
Immunotherapy for MIS-C - IVIG, Glucocorticoids, and Biologics.
-
Randomized Controlled Trial Comparative Study
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. ⋯ Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).